… and safety of nirmatrelvir/ritonavir (Paxlovid) with molnupiravir … difference between
nirmatrelvir/ritonavir and molnupiravir in … In terms of safety, although the incidence of any adverse …

… Drug interactions are a major concern for nirmatrelvir-ritonavir. Nirmatrelvir-ritonavir
demonstrated a greater risk reduction in hospitalization and death than molnupiravir compared to …

… Moreover, in order to reduce possible bias induced by different criteria that clinicians could
have applied to prescribe either molnupiravir or nirmatrelvir/ritonavir, we perform a logistic …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

… This advantage disappears when we compared nirmatrelvir/ritonavir with molnupiravir.
Finally, we found that about 2% of patients treated with nirmatrelvir/ritonavir and molnupiravir …

… also benefit from nirmatrelvir–ritonavir and molnupiravir among … DH) has approved
nirmatrelvir–ritonavir and molnupiravir for … were prescribed molnupiravir or nirmatrelvir–ritonavir, …

… There are no available data on the use of molnupiravir or nirmatrelvir/ritonavir in pregnant
or lactating women (19, 22). Embryo-fetal developmental studies of nirmatrelvir were …

… were treated with molnupiravir; otherwise, nirmatrelvir/ritonavir was the treatment of …
nirmatrelvir/ritonavir twice daily or 800 mg of molnupiravir twice daily. In case of nirmatrelvir/ritonavir …

… In this retrospective cohort study, we aimed to evaluate clinical and virological outcomes
following the use of molnupiravir or nirmatrelvir–ritonavir in patients with COVID-19 during a …

… Nirmatrelvir-ritonavir is used in patients with coronavirus disease 2019 (COVID-19) with …
evaluating the safety and efficacy of nirmatrelvir-ritonavir when compared with molnupiravir in …